The article linked and excerpted below points of an important change in thinking for conventional oncology. Cancer patients die because their cancer becomes resistant to chemotherapy. If you can figure out a way to make the cancer vulnerable to chemo then the cancer will die.
There are a host of evidence-based, non-toxic therapies that research has shown enhance the efficacy of chemo. I supplement with curcumin, resveritrol, omega-3 fatty acids, and others regularly. Curcumin is cytotoxic to my cancer, multiple myeloma, and it also enhances the efficacy of many different conventional chemotherapy regimens.
Have you or a loved one been diagnosed with ALL? Please scroll down the page, post a question or comment and I will reply to you ASAP.
“Scientists at Griffith University’s Institute for Glycomics and The Saban Research Institute of Children’s Hospital Los Angeles have discovered a critical weakness in leukaemic cells, which may pave the way to new treatments.
The research team has demonstrated that leukaemic cells can be eradicated by removing a carbohydrate modification displayed on the cell’s surface.
Director of Griffith University’s Institute for Glycomics, Professor Mark von Itzstein is the Australian team leader. He said the discovery is an important advance against leukemia, a cancer of malignant white blood cells that multiply uncontrollably. Acute lymphoblastic leukemia (ALL) is the most common childhood cancer.
“We have found that the leukaemic cell has an altered cell surface carbohydrate decoration compared to normal cells and this also conveys resistance to drug treatment,” Professor von Itzstein said.
“We have now shown that with the removal of this carbohydrate alteration the cells die…”
Professor von Itzstein said the research could lead to new ways to fight the disease, particularly where it has become treatment resistant.
“Up until 40 years ago, only one child in five survived ALL,” but advances in chemotherapy have changed that outcome and now nearly 80 percent of children with ALL will be cured,” Professor von Itzstein said.
“For the remaining 20 percent, however, the disease returns necessitating additional rounds of intensive chemotherapy. Unfortunately, most relapsed patients die within one year because their cancer cells are resistant to chemotherapy.
“In the future, we hope that this novel, structural approach to treating ALL may offer an effective treatment option for children battling drug-resistant forms of the disease…”
“By exploiting this ‘Achilles heel’ in these leukaemic cells, our collaborative research efforts are now focused on the development of a new type of drug therapy that targets this carbohydrate modification.”